Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464
Kort samengevat
Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today that the first patient was dosed in study ABX464-301, a phase 2a clinical trial of…
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij BioSpace.
Lees het volledige bericht ↗